Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2136836 | 0.84 | KDM4C (0.38) | KDM4CMAPTALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL4066157 | 0.79 | ACVRL1 (0.38) | KDM4CMEN1KMT2A | |
| SCHEMBL17240400 | 0.76 | EPAS1 (0.30) | KDM4C | |
| SCHEMBL22773671 | 0.75 | FFAR4 (0.37) | POLB | |
| SCHEMBL22787209 | 0.75 | PPARD (0.32) | POLB | |
| SCHEMBL2140560 | 0.74 | ALDH1A1 (0.40) | KDM4CMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2135916 | 0.72 | TAOK1 (0.44) | KDM4CMAPTALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL14884996 | 0.70 | UGT2B17 (0.41) | POLB | |
| SCHEMBL10287035 | 0.70 | POLB (0.36) | POLB | |
| SCHEMBL12696397 | 0.70 | ACHE (0.37) | ALDH1A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632899-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-2435407-B1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2019-12-25 | — | — | EP | disclosed |
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| CN-105254557-A | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC | 2016-01-20 | — | — | CN | disclosed |
| CN-105130957-A | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC | 2015-12-09 | — | — | CN | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| WO-2010137351-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | KDM4C 957/4885MAPT 2691/4885ALDH1A1 2895/4885 |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | KDM4C 955/4885MAPT 2659/4885ALDH1A1 2882/4885 |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | KDM4C 583/4885MAPT 4719/4885ALDH1A1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.